136.44
3.81 (2.87%)
| Previous Close | 132.63 |
| Open | 133.97 |
| Volume | 767,021 |
| Avg. Volume (3M) | 671,691 |
| Market Cap | 7,680,309,760 |
| Price / Earnings (TTM) | 13,644.00 |
| Price / Earnings (Forward) | 70.92 |
| Price / Sales | 10.52 |
| Price / Book | 3.58 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2026 |
| Profit Margin | -3.53% |
| Operating Margin (TTM) | 5.59% |
| Diluted EPS (TTM) | -0.420 |
| Quarterly Revenue Growth (YOY) | 10.40% |
| Quarterly Earnings Growth (YOY) | 76.90% |
| Total Debt/Equity (MRQ) | 34.44% |
| Current Ratio (MRQ) | 6.79 |
| Operating Cash Flow (TTM) | 145.69 M |
| Levered Free Cash Flow (TTM) | 183.66 M |
| Return on Assets (TTM) | 0.92% |
| Return on Equity (TTM) | -1.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Repligen Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 6.41% |
| % Held by Institutions | 105.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| United Capital Financial Advisors, Llc | 30 Sep 2025 | 2,755,943 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 200.00 (Barclays, 46.59%) | Buy |
| 200.00 (UBS, 46.59%) | Buy | |
| Median | 200.00 (46.59%) | |
| Low | 190.00 (Wells Fargo, 39.26%) | Buy |
| Average | 196.67 (44.14%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 161.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 16 Jan 2026 | 200.00 (46.58%) | Buy | 162.02 |
| Barclays | 15 Dec 2025 | 200.00 (46.58%) | Buy | 160.58 |
| Wells Fargo | 15 Dec 2025 | 190.00 (39.26%) | Buy | 160.58 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair |
| 18 Dec 2025 | Announcement | Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference |
| 16 Dec 2025 | Announcement | Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows |
| 26 Nov 2025 | Announcement | Repligen Corporation to Present at Evercore Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |